Race Oncology Limited

ASX:RAC.AX

1.55 (AUD) • At close November 4, 2024
Bedrijfsnaam Race Oncology Limited
Symbool RAC.AX
Munteenheid AUD
Prijs 1.55
Beurswaarde 264,233,150
Dividendpercentage 0%
52-weken bereik 0.64 - 2.09
Industrie Biotechnology
Sector Healthcare
CEO Dr. Peter M. Smith Ph.D.
Website https://www.raceoncology.com

An error occurred while fetching data.

Over Race Oncology Limited

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which

Vergelijkbare Aandelen

Aroa Biosurgery Limited logo

Aroa Biosurgery Limited

ARX.AX

0.57 AUD

Paradigm Biopharmaceuticals Limited logo

Paradigm Biopharmaceuticals Limited

PAR.AX

0.22 AUD

Pacific Smiles Group Limited logo

Pacific Smiles Group Limited

PSQ.AX

1.9 AUD

Rhythm Biosciences Limited logo

Rhythm Biosciences Limited

RHY.AX

0.1 AUD

Cogstate Limited logo

Cogstate Limited

CGS.AX

0.975 AUD

Starpharma Holdings Limited logo

Starpharma Holdings Limited

SPL.AX

0.098 AUD

Anteris Technologies Ltd logo

Anteris Technologies Ltd

AVR.AX

10.21 AUD

PYC Therapeutics Limited logo

PYC Therapeutics Limited

PYC.AX

0.19 AUD

Immutep Limited logo

Immutep Limited

IMM.AX

0.28 AUD

AnteoTech Limited logo

AnteoTech Limited

ADO.AX

0.027 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)